A systematic review and meta-analysis examined the relationship between GLP-1 (glucagon-like peptide-1 receptor agonist) drugs and diabetic retinopathy (retinal damage caused by diabetes)[5]. The research included an analysis of 39 articles (24 randomized clinical trials and 15 observational studies), of which 27 were included in the meta-analysis[5]. A pooled analysis showed that GLP-1 drugs were not significantly associated with the risk of diabetic retinopathy compared to other treatments (pooled RR = 0.98, 95% CI 0.71–1.35)[5]. Similar results without statistical significance were also found in subgroups according to study type – randomized clinical trials had a pooled RR of 0.86 (95% CI 0.69–1.05) and observational studies RR 1.86 (95% CI 0.57–6.06)[5]. Even after excluding studies with a high risk of bias, the estimate remained without statistical significance (RR = 1.03, 95% CI 0.66–1.61)[5]. The authors state that the current evidence is incomplete and recommend further long-term, high-quality studies to clarify the long-term safety of these drugs for the eyes[5].